[go: up one dir, main page]

EA201490957A1 - TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES WITH ANTI-CXCR4 ANTIBODY - Google Patents

TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES WITH ANTI-CXCR4 ANTIBODY

Info

Publication number
EA201490957A1
EA201490957A1 EA201490957A EA201490957A EA201490957A1 EA 201490957 A1 EA201490957 A1 EA 201490957A1 EA 201490957 A EA201490957 A EA 201490957A EA 201490957 A EA201490957 A EA 201490957A EA 201490957 A1 EA201490957 A1 EA 201490957A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cxcr4
cxcr4 antibody
subject
treatment
malignant diseases
Prior art date
Application number
EA201490957A
Other languages
Russian (ru)
Other versions
EA026153B1 (en
Inventor
Мишель Р. Кунэ
Чинь Пань
Джозефин М. Кардарелли
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201490957A1 publication Critical patent/EA201490957A1/en
Publication of EA026153B1 publication Critical patent/EA026153B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение предусматривает человеческие моноклональные антитела, которые специфически связывают CXCR4 с высокой аффинностью. Настоящее изобретение также предусматривает способ лечения субъекта, страдающего раком, экспрессирующим CXCR4, в частности гематологическим злокачественным заболеванием, таким как множественная миелома, острая миелоидная лимфома или неходжкинская лимфома, включающий введение субъекту терапевтически эффективного количества фармацевтической композиции, включающей анти-СХСR4 антитело по изобретению. Изобретение также описывает набор для лечения рака у субъекта, включающий дозу анти-CХCR4 антитела и инструкции для применения анти-CХCR4 антитела в способах лечения по изобретению.The present invention provides human monoclonal antibodies that specifically bind CXCR4 with high affinity. The present invention also provides a method for treating a subject suffering from cancer expressing CXCR4, in particular a hematologic malignant disease such as multiple myeloma, acute myeloid lymphoma or non-Hodgkin lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the invention. The invention also describes a kit for treating cancer in a subject, comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the treatment methods of the invention.

EA201490957A 2011-11-09 2012-11-09 Treatment of hematologic malignancies with an anti-cxcr4 antibody EA026153B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557815P 2011-11-09 2011-11-09
US201161569113P 2011-12-09 2011-12-09
PCT/US2012/064395 WO2013071068A2 (en) 2011-11-09 2012-11-09 Treatment of hematologic malignancies with an anti-cxcr4 antibody

Publications (2)

Publication Number Publication Date
EA201490957A1 true EA201490957A1 (en) 2014-08-29
EA026153B1 EA026153B1 (en) 2017-03-31

Family

ID=47179025

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490957A EA026153B1 (en) 2011-11-09 2012-11-09 Treatment of hematologic malignancies with an anti-cxcr4 antibody

Country Status (24)

Country Link
US (2) US10428151B2 (en)
EP (1) EP2776032B1 (en)
JP (1) JP6541350B2 (en)
KR (1) KR102024957B1 (en)
CN (1) CN104039320B (en)
AU (1) AU2012335553B2 (en)
BR (1) BR112014011144A2 (en)
CA (1) CA2855155A1 (en)
CY (1) CY1121331T1 (en)
DK (1) DK2776032T3 (en)
EA (1) EA026153B1 (en)
ES (1) ES2705001T3 (en)
HR (1) HRP20182183T1 (en)
HU (1) HUE043001T2 (en)
IL (1) IL232517B (en)
LT (1) LT2776032T (en)
MX (1) MX357100B (en)
PL (1) PL2776032T3 (en)
PT (1) PT2776032T (en)
RS (1) RS58102B1 (en)
SG (1) SG11201401386XA (en)
SI (1) SI2776032T1 (en)
SM (1) SMT201900026T1 (en)
WO (1) WO2013071068A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066351B1 (en) * 2006-10-02 2015-09-09 E. R. Squibb & Sons, L.L.C. Human antibodies that bind cxcr4 and uses thereof
EP2726634B1 (en) 2011-07-01 2017-02-22 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
JP2016527303A (en) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド Inhibition of CXCR4 signaling in cancer immunotherapy
EP3044338B1 (en) 2013-09-12 2021-11-24 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
EP3599248A1 (en) 2013-11-06 2020-01-29 Bristol-Myers Squibb Company Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody
WO2015085075A1 (en) 2013-12-06 2015-06-11 Dana-Farber Cancer Institute, Inc. Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CN113072644A (en) 2013-12-17 2021-07-06 埃姆医疗有限公司 Means and methods for combating myeloproliferative or lymphoproliferative disorders
US10066014B2 (en) * 2014-02-06 2018-09-04 Yeda Research And Development Co. Ltd. Anti CD84 antibodies, compositions comprising same and uses thereof
CN106794219A (en) * 2014-02-19 2017-05-31 北京迈康斯德医药技术有限公司 Chemokine receptors antagonist and its conjoint therapy
LT3242685T (en) * 2015-01-09 2022-08-25 Adalta Limited Cxcr4 binding molecules
LT3283107T (en) 2015-04-17 2020-09-10 Bristol-Myers Squibb Company A COMPOSITION INCLUDING A COMBINATION OF IPILIMUMAB AND NIVOLUMAB
EA201792522A1 (en) 2015-06-12 2018-05-31 Бристол-Майерс Сквибб Компани TREATMENT OF MALIGNANT TUMOR WITH THE HELP OF THE COMBINED BLOCK OF SIGNAL PATH OF PD-1 AND CXCR4
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
KR20180063885A (en) * 2015-09-24 2018-06-12 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Methods and compositions for reducing metastasis
WO2017083440A1 (en) * 2015-11-09 2017-05-18 The General Hospital Corporation D.B.A Massachusetts General Hospital Unit dose formulations for use as an anti-fugetactic agent
ES2830726T3 (en) * 2016-02-23 2021-06-04 Biolinerx Ltd Method for selecting a treatment regimen for acute myeloid leukemia (AML)
CA3019182A1 (en) 2016-04-29 2017-11-02 Dana-Farber Cancer Institute, Inc. Hck as a therapeutic target in myd88 mutated diseases
US11400155B2 (en) 2016-05-20 2022-08-02 Biohaven Therapeutics Ltd. Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers
CN109640979A (en) * 2016-06-16 2019-04-16 国家科学研究中心 For reducing the compound of Interferon level
CN116903741A (en) 2016-06-20 2023-10-20 科马布有限公司 Antibodies or antigen binding fragments thereof that specifically bind to PD-L1 and uses thereof
US20190389958A1 (en) * 2017-01-31 2019-12-26 Msm Protein Technologies, Inc. Anti-cxcr4 antibodies
KR20200090982A (en) * 2017-02-21 2020-07-29 쿠라 온콜로지, 인크. Methods of treating cancer with farnesyltransferase inhibitors
CN110494450A (en) 2017-03-31 2019-11-22 百时美施贵宝公司 The method for treating tumour
JP2020536894A (en) 2017-10-15 2020-12-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tumor treatment
US20210162009A1 (en) * 2017-12-08 2021-06-03 The Medical College Of Wisconsin, Inc. Chemokine variants as immune stimulants
KR102693317B1 (en) * 2018-03-13 2024-08-07 푼다시온 파라 라 인베스티가시온 바이오메디카 델 호스피탈 우니베르시타리오 라 파즈 Anti-CXCR4 Antibody in Combination with Activated and Expanded Natural Killer Cells for Cancer Immunotherapy
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
CN111918873B (en) 2018-03-27 2025-06-24 百时美施贵宝公司 Real-time titer monitoring using UV signal
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
EP3973274A1 (en) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Methods of monitoring cell culture media
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4490166A1 (en) 2022-03-09 2025-01-15 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
IL322179A (en) * 2023-01-30 2025-09-01 Kymab Ltd Antibodies
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
CN119119196B (en) * 2024-08-01 2025-09-09 青岛大学 Motixafortide-camptothecin-based conjugate and preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2117953C (en) 1993-10-14 2001-12-11 Tasuku Honjo Human stromal derived factor 1 alpha and 1 beta and dnas encoding the same
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
ATE378403T1 (en) 2000-11-30 2007-11-15 Medarex Inc TRANSCHROMOSOMAL TRANSGENIC RODENTS FOR PRODUCING HUMAN ANTIBODIES
EP1660654B1 (en) 2003-09-04 2011-11-09 Medarex, Inc. Expression vector
US8329178B2 (en) 2005-02-18 2012-12-11 Dana-Farber Cancer Institute, Inc. Antibodies against CXCR4 and methods of use thereof
US8569280B2 (en) * 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
US8258098B2 (en) * 2006-02-28 2012-09-04 Pharma Mar, S.A. Antitumoral treatments
EP2066351B1 (en) 2006-10-02 2015-09-09 E. R. Squibb & Sons, L.L.C. Human antibodies that bind cxcr4 and uses thereof
FR2915102B1 (en) 2007-04-23 2014-05-16 Pf Medicament USE OF ANTI-CXCR4 ANTIBODY FOR THE TREATMENT OF CANCER
CA2724409A1 (en) 2008-05-14 2009-11-19 Eli Lilly And Company Anti-cxcr4 antibodies
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
WO2010105008A2 (en) * 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
CN102460165B (en) 2009-05-19 2016-08-17 维维雅生物技术公司 Method for providing ex vivo personalized drug testing for hematological malignancies
JP5655147B2 (en) 2010-08-20 2015-01-14 セルリアン・ファーマ・インコーポレイテッド Therapeutic peptide-polymer conjugates, particles, compositions and related methods

Also Published As

Publication number Publication date
MX2014005267A (en) 2014-07-28
CA2855155A1 (en) 2013-05-16
AU2012335553A1 (en) 2014-07-03
IL232517A0 (en) 2014-06-30
BR112014011144A2 (en) 2017-05-16
HUE043001T2 (en) 2019-07-29
EA026153B1 (en) 2017-03-31
CN104039320B (en) 2019-10-15
LT2776032T (en) 2018-12-10
ES2705001T3 (en) 2019-03-21
US10428151B2 (en) 2019-10-01
US20200231683A1 (en) 2020-07-23
PT2776032T (en) 2019-01-21
EP2776032A2 (en) 2014-09-17
JP2014533279A (en) 2014-12-11
SMT201900026T1 (en) 2019-05-10
WO2013071068A2 (en) 2013-05-16
WO2013071068A3 (en) 2013-07-18
RS58102B1 (en) 2019-02-28
IL232517B (en) 2018-05-31
HRP20182183T1 (en) 2019-02-22
SI2776032T1 (en) 2018-12-31
SG11201401386XA (en) 2014-10-30
DK2776032T3 (en) 2019-02-04
CY1121331T1 (en) 2020-05-29
KR102024957B1 (en) 2019-09-24
CN104039320A (en) 2014-09-10
MX357100B (en) 2018-06-26
JP6541350B2 (en) 2019-07-10
EP2776032B1 (en) 2018-10-17
PL2776032T3 (en) 2019-03-29
US20140322208A1 (en) 2014-10-30
AU2012335553B2 (en) 2017-09-21
KR20140093945A (en) 2014-07-29

Similar Documents

Publication Publication Date Title
EA201490957A1 (en) TREATMENT OF HEMATOLOGICAL MALIGNANT DISEASES WITH ANTI-CXCR4 ANTIBODY
JOP20200237A1 (en) Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
EA201490622A1 (en) AGENTS CONNECTING GROWTH ENDOTHELIUM GROWTH FACTOR (VEGF) / DELTA-LIKAND (DLL4), AND THEIR APPLICATION
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
UA116194C2 (en) ANTIBODY THAT SPECIFICALLY Binds to HUMAN ALPHA SYNUCLEIN
UA112743C2 (en) THERAPEUTIC DLL4 Binding Protein
EA201590144A1 (en) RSPO3-BINDING AGENTS AND THEIR APPLICATION
EA200702053A1 (en) ANTIBODIES AGAINST CD38 FOR THE TREATMENT OF MULTIPLE MYELOMA
MX349198B (en) Rspo binding agents and uses thereof.
MX369148B (en) Kir3dl2 binding agents.
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
UA113623C2 (en) TISSUE FACTOR FACTOR (TFPI) MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR
EA201892184A1 (en) OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR
EA201892541A1 (en) HUMANIZED ANTI-IL-1R3 ANTIBODIES
MX2025010217A (en) Anti-cd3 multispecific antibodies and methods of use
EA202092151A1 (en) ANTIBODIES
EA201991227A1 (en) ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20
UA108207C2 (en) HIGH-AFIN HUMAN ANTIBODY TO HUMAN ANGIOPOETIN-2

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU